A 185-acre campus that will integrate advanced manufacturing and laboratory technologies with AI to support the production of the company’s immunology, neuroscience and oncology medicines.

The project will create about 734 jobs in engineering, manufacturing operations and other technical roles and will generate more than 2,000 construction jobs during campus development.

Part of a larger, previously announced $100 billion company investment.

An expansion of a manufacturing facility that will increase production of life-sustaining, plasma-derived therapies for people living with rare and serious diseases and other acute medical issues. The development will add at least 300 jobs.

Added details made public for an original November 2025 announcement.

A new 46,000-square-foot radioligand therapy (RLT) manufacturing site, the company’s fifth in the US and first manufacturing facility in Texas.

Part of a larger, previously announced $23 billion company investment.

Two new active pharmaceutical ingredient (API) manufacturing facilities that will integrate advanced manufacturing technologies with artificial intelligence to support the production of next-generation neuroscience and obesity medications. To support these new facilities, AbbVie will hire 300 people in North Chicago, including engineers, scientists, manufacturing operators and lab technicians.

Part of a larger, previously announced $100 billion company investment.

New next-generation cell therapy manufacturing facility that will support 500 skilled biomanufacturing jobs and more than 4,000 construction jobs during the site's development. Expanded details for a project first announced in January 2026.

Part of a larger, previously announced $55 billion company investment.

A new injectable medicine and device manufacturing facility that will produce next-generation weight-loss therapies. The project will bring 850 high-value jobs to the Lehigh Valley area, including engineers, scientists, operations personnel and lab technicians.

Part of a larger, previously announced $27 billion company investment.

An expansion of Genentech’s (Roche’s U.S. subsidiary) initial $700 million investment in a new fill-finish biologics plant, bringing the total investment in this facility to $2 billion.

The expanded investment will include additional production capacity and support an additional 100 new jobs once completed.

Part of a larger, previously announced $50 billion company investment.

Pledging an additional $90 billion toward U.S.-based research and development and capital investments, including manufacturing, over the next decade to bring the company’s total commitment to $100 billion.

AbbVie previously committed to a $10 billion U.S. expansion in April 2025.